The estimated Net Worth of Howard Lee is at least $7.49 Milion dollars as of 1 June 2023. Howard Lee owns over 16,679 units of Amphastar Pharmaceuticals Inc stock worth over $7,193,983 and over the last 10 years he sold AMPH stock worth over $0. In addition, he makes $299,507 as Independent Director at Amphastar Pharmaceuticals Inc.
Howard has made over 12 trades of the Amphastar Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 16,679 units of AMPH stock worth $278,373 on 1 June 2023.
The largest trade he's ever made was exercising 38,462 units of Amphastar Pharmaceuticals Inc stock on 15 December 2015 worth over $449,236. On average, Howard trades about 8,311 units every 114 days since 2014. As of 1 June 2023 he still owns at least 159,618 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Howard Lee stock trades at the bottom of the page.
Dr. Howard S. Lee Ph.D. serves as Independent Director of the Company. He has served as a member of our board of directors since August 2007. He previously served as a member of the board of our subsidiary, IMS, from 1998 to 2002 and on our board of directors from 2002 to 2004. Dr. Lee is currently the partner at the CID Group, a prominent investment group in the greater China area, where he has worked since March 2012. From 2009 to 2010 he was the Chief Investment Officer at UniMed Venture Management Inc., a biotech venture capital firm. Prior to joining UniMed in July 2009, he was a Managing Director at Silver Biotech Management, Inc. from July 2006 to June 2009. Dr. Lee served as President and CEO of CDIB Biotech USA Investment Co. Ltd. from 2000 to 2006 and as Vice President of China Development Industrial Bank, an investment bank in Taiwan, from October 1995 to June 2006. Dr. Lee earned his B.Sc. at Fu-Jen University (Taiwan), his M.Sc. and Ph.D. degrees in chemistry from the University of Southern California in Los Angeles and completed his postdoctoral research at the Loker Hydrocarbon Research Institute of the University of Southern California.
As the Independent Director of Amphastar Pharmaceuticals Inc, the total compensation of Howard Lee at Amphastar Pharmaceuticals Inc is $299,507. There are 12 executives at Amphastar Pharmaceuticals Inc getting paid more, with Jack Zhang having the highest compensation of $5,969,740.
Howard Lee is 57, he's been the Independent Director of Amphastar Pharmaceuticals Inc since 2007. There are 12 older and 4 younger executives at Amphastar Pharmaceuticals Inc. The oldest executive at Amphastar Pharmaceuticals Inc is Richard Koo, 79, who is the Independent Director.
Howard's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins oraz William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: